Dear Colleagues,

On behalf of the Clinical Immunology Society (CIS), thank you for participating in the 2013 Update in Primary Immunodeficiency Diseases taking place April 25, 2013 at the JW Marriott Marquis in Miami, FL.

CIS is the key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology and to promote excellence in the care of patients with immunologic/inflammatory disorders.

Derived from the need to understand how to treat primary immune deficiency diseases in the context of other diseases, the CIS developed the Update in Primary Immunodeficiency Diseases which is geared toward physicians and scientists who are involved in the evaluation and/or care of patients with primary immune deficiencies.

The organizers are excited about this new program and hope you find the meeting useful and exciting!

Sincerely,

Charlotte Cunningham-Rundles, MD, PhD
Mt. Sinai School of Medicine

Steven M. Holland, MD
NIAID, NIH

Kathleen E. Sullivan, MD, PhD
Children’s Hospital of Philadelphia

Troy Torgerson, MD, PhD
University of Washington

---

TABLE OF CONTENTS

2013 Update in Primary Immunodeficiency Diseases Supporters ........ Pg. 2
About CIS ......................................................... Pg. 3
General Meeting Information ........................................ Pg. 11
Continuing Medical Education Information ................................ Pg. 12
Speakers Disclosures .............................................. Pg. 13
Miami Visitor Information .......................................... Pg. 14
Schedule of Events ................................................ Pg. 16
Exhibit Hall Floor Plan ............................................. Pg. 17
Exhibitor Listing ................................................ Pgs. 17-19
Poster Listing ....................................................... Pgs. 20-23

2013 UPDATE IN PID ORGANIZERS

Charlotte Cunningham-Rundles, MD, PhD
Mt. Sinai School of Medicine
New York, NY

Steven M. Holland, MD
NIAID, NIH
Bethesda, MD

Kathleen E. Sullivan, MD, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA

Troy Torgerson, MD, PhD
University of Washington
Seattle, WA
The Clinical Immunology Society (CIS), established in 1986, is the key interdisciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. CIS is an international professional organization which includes more than 650 clinicians, investigators, and trainees.

The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

The primary objectives and purposes of CIS are to:
- facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunological/inflammatory diseases;
- promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
- encourage investigators and clinicians to share in their knowledge of immunologically active drugs and other interventions;
- promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation; and
- foster excellence in research and medical practice.
Submit a Manuscript

The *Journal of Clinical Immunology* accepts manuscripts in the areas of human, basic, and clinical immunology and molecular biology. The areas of basic immunology include (but are not limited to) studies of lymphocytes, antigen presenting cells, neutrophils, natural killer cells, complement components, immunoglobulins, antibodies, cytokines and their receptors, immunoregulation, signal transduction, T-cell receptors, and immunoglobulin genes. Papers on animal models of human diseases are welcome. Articles dealing with molecular biology related to human diseases are accepted. Special Articles are by invitation only. Case reports will only be considered if they are linked to novel findings/science or are accompanied by an extensive review of the relevant medical literature to the findings of the case report.

Authors, editors and reviewers of *Journal of Clinical Immunology* use our fully web-enabled online manuscript submission and review system. To keep the review time as short as possible, we request authors to submit manuscripts online to the journal's editorial office. Our online manuscript submission and review system offers authors the option to track the progress of the review process of manuscripts in real time.

To submit a manuscript, please visit http://www.editorialmanager.com/joci/

About the Journal

The *Journal of Clinical Immunology* is a bimonthly international journal that helps researchers and academic clinicians keep current on investigative basic immunology and diseases related to the immune system. This well-established journal publishes articles on basic, translational, and clinical studies in all aspects of immunology, including animal models of human diseases. The OnlineFirst™ feature allows articles to be viewed through the journal’s website before they are available in the printed journal. The *Journal of Clinical Immunology* is the official journal of the Clinical Immunology Society.
MISSION STATEMENT
The mission of the Clinical Immunology Society is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

ABOUT CIS: OBJECTIVES AND PURPOSES
The Clinical Immunology Society (CIS), established in 1986, is devoted to fostering developments in the science and practice of clinical immunology. The primary objectives and purposes of this Society shall be to:
1. facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunologic/inflammatory diseases;
2. promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
3. encourage investigators and clinicians to share their knowledge of immunologically active drugs and other interventions;
4. promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation and;
5. foster excellence in research and medical practice.

MEMBERSHIP BENEFITS
The benefits of membership in the Clinical Immunology Society include:
• The opportunity to be involved in a dynamic society devoted to fostering the development of clinical immunology.
• Reduced registration fees to the CIS Annual Meeting & Primary Immune Deficiency National Conference.
• Complimentary online subscription to the Journal of Clinical Immunology, the official peer-reviewed scientific journal of the Clinical Immunology Society;
• Opportunities to advance your career by serving on CIS Committees or serving as faculty for CIS Schools and meetings;
• Belonging to an association that is accredited by the Accreditation Council for Continuing Medical Education to sponsor CME for physicians;
• Reduced FOCUS Annual Meeting Registration fees;
• Access to virtual meeting content through the CIS website.

MEMBERSHIP CATEGORIES AND REQUIREMENTS
Regular membership shall be open to those individuals who:
• are engaged in research in the area of clinical immunology or have contributed to or are engaged in the practice of clinical immunology;
• have an MD, DO, PhD or equivalent academic degree;
• are active, bona fide representatives of the international scientific community with a specialty or interest in a field related to clinical immunology.

Associate membership shall be open to those individuals who:
• hold a Bachelors, Masters, RN or equivalent degree with a demonstrated interest in clinical immunology.

Trainee membership shall be open to those individuals who:
• are enrolled in academic programs awarding, and are candidates for, MD, DO, PhD, or equivalent degree, with a demonstrated interest in clinical immunology.
• are participating in post-doctoral or clinical fellowship, or residency programs.

DEVELOPING COUNTRIES
Applicants from developing countries are eligible for a reduced dues rate of $50.00 upon request.

APPLICATION PROCESS
Applicants for Regular and Associate membership must submit:
• a CIS membership application;
• a current curriculum vitae;
• the first year’s dues with application.

Applicants for Trainee membership must submit:
• a CIS membership application;
• the first year’s dues with application;

CLINICAL IMMUNOLOGY SOCIETY
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Telephone: 414.224.8095 Fax: 414.272.6070
info@clinimmsoc.org www.clinimmsoc.org
CIS 2013 MEMBERSHIP APPLICATION

First Name ___________________________________________ Middle Initial _______ Last Name __________________________

Designation (MD, PhD, other) __________________________ Current Position/Title ________________________________

Date of Birth __________________________ Training Start Date __________________________ Training End Date __________________

Institution __________________________________________

Current Research Interest(s) (up to 3) __________________________ __________________________ __________________________

Preferred Mailing Address: ☐ Business ☐ Home

Business Address __________________________________________

City __________________________ State _______ Postal Code/Country __________________________

Business Phone __________________________ Fax __________________________

E-mail _____________________________________________________________________________

Home Address __________________________________________

City __________________________ State _______ Postal Code/Country __________________________

Home Phone __________________________________________________________________________

PLEASE SELECT TO BE LISTED ON THE FIND AN IMMUNOLOGIST DIRECTORY:
☐ I would like to be listed in the on-line Find an Immunologist Referral Directory

□ must be clinically active to qualify

JOURNAL OF CLINICAL IMMUNOLOGY – OFFICIAL JOURNAL OF THE CLINICAL IMMUNOLOGY SOCIETY

As a CIS member you are entitled to receive electronic access. You may add a print subscription for an additional $20.

☒ I DO wish to receive the print subscription to the CIS Journal at a cost of $20.

AFFILIATIONS (CHECK ALL THAT APPLY):
☐ Industry ☐ Medical School ☐ Military ☐ Other _______

□ Private Practice ☐ Research University ☐ NIH/FDA

SPECIALTY (CHECK ALL THAT APPLY):
☐ Allergy/Asthma/Pulmonary ☐ Immunodeficiency

☐ Autoimmunity ☐ Immunogenetics

☐ Cardiovascular ☐ Immunotherapy

☐ Cytokines ☐ MS/Neuroimmunology

☐ Dermatology ☐ Mucosal Immunology

☐ Diagnostic/Laboratory Pathology

☐ Immunology ☐ Ophthalmology

☐ Endocrinology ☐ Reproductive Immunology

☐ Gastroenterology ☐ Rheumatology

☐ Hematology ☐ Transplantation

☐ HIV/Infectious Diseases ☐ Tumor Immunology

☐ Histocompatibility ☐ Other __________________________

MEMBERSHIP CATEGORY

☐ Regular – 3+ years out of training ........................................ $200*

☐ Regular – 2 years out of training/training completed in 2008 ........................ $125*

☐ Regular – 1 year out of training/training completed in 2009 .......................... $50*

☐ Associate ........................................................ $175*

Documents required for Regular & Associate Membership:
☐ Current Curriculum Vitae

☐ Trainee. __________________________

☑ Name of training program director __________________________

Documents required for Trainee Membership

☐ Attestation Statement

*Due must be submitted with your application.

DEVELOPING COUNTRIES

☐ As an applicant from a developing country I am requesting the reduced dues rate of $50.00.

PLEASE CONSIDER MAKING A DONATION TO CIS

☐ General Donation Amount: $ __________________________

☐ Educational Programs Amount: $ __________________________

TOTAL AMOUNT ENCLOSED / AUTHORIZED TO CHARGE $ __________________________

PAYMENT METHOD:

☐ Check (in US dollars payable to Clinical Immunology Society)

☐ VISA ☐ DISCOVER ☐ MASTERCARD ☐ AMERICAN EXPRESS

Cardholder Name __________________________ Cardholder Signature __________________________

Card Account Number __________________________

Expiration Date _______ 3 Digit Security Code __________________________

(4 Digits for AmEx)
APPLICATION FOR CIS-PIDD LIST SERVICE ACCESS

CIS-PIDD is a professional group of physicians and scientists with an interest in primary immunodeficiencies. The purpose of the group is to enhance collaborations and exchange information among members. We welcome physicians who provide care for patients with immunodeficiencies and scientists who are doing research related to the primary immunodeficiencies who wish to join our group.

This list service is managed by the Clinical Immunology Society. Completed applications must be sent to CIS by email, fax or the postal service to the following address:

CLINICAL IMMUNOLOGY SOCIETY
555 East Wells Street, Suite 1100
Milwaukee, WI 53202/USA
Email: info@clinimmmsoc.org
Telephone: 414.224.8095 - Fax: 414.272.6070

Name ____________________________________________________________

Department ______________________________________________________

Institution _______________________________________________________

Address _________________________________________________________

City ________________________________ Postal Code ____________________

Country _________________________________________________________

Phone ___________________________ Fax _______________________________

Email address ____________________________________________________

Basis of interest in CIS-PIDD list service: ____________________________________

_____________________________________________________________________

_____________________________________________________________________

_____________________________________________________________________

_____________________________________________________________________
DISCLAIMER

The communication provided by this list service is for educational or informational purposes only and is not intended to replace or constitute medical advice or treatments.

CIS intends that the information discussed on this list service is accurate. However, these discussions are between CIS-PIDD list service members. Therefore, CIS disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this service, including without limitation merchantability or fitness for any particular purpose. In no event shall CIS be liable for any indirect, special, incidental or consequential damages arising out of any use of or reliance on any content or materials contained herein.

The list service is provided “AS IS” without any warranty, of any kind, express or implied. Neither CIS is responsible for any content posted by any user of this service. Any opinion expressed by a user does not necessarily represent the opinion of CIS and the user is solely responsible for same.

CIS does not assume and hereby disclaims any and all liability to any person or entity for any claims, damages, liability or other loss including, without limitation, any liability for injury or other damage resulting from any use of or reliance on this service or from the posting of any content or material by any third party.

No use of, or reliance on, information included on this list service shall be deemed to give rise to a physician-patient relationship. No information presented shall be deemed to present the only or necessarily the best method or procedure with respect to a matter discussed on this service; rather, any such material shall be acknowledged as only the approach or opinion of the discussant. The user assumes all risks of using the information discussed on this list service.

I would like to join the CIS-PIDD List Service and agree to abide by the guidelines.

Signature: ___________________________ Date: ___________________________
APPLICATION FOR CIS-AUTOIMMUNE POLYENDOCRINE SYNDROMES (APS) LIST SERVICE PARTICIPATION

The Autoimmune Polyendocrine Syndromes (APS) list service is a professional email group of physicians and scientists with an interest in APS. The purpose of the group is to enhance collaborations and exchange information among participants. We welcome physicians and researchers who have a special interest in autoimmune polyendocrine syndromes including the clinical care of patients and research into the pathophysiology, natural history and possible treatments for these disorders to join our group.

PLEASE PRINT OR TYPE AND RETURN COMPLETED FORM TO THE CIS NATIONAL OFFICE

Name ____________________________________________________________
Department ____________________________________________________________
Institution ____________________________________________________________
Address ____________________________________________________________
City ___________________________ Postal Code ____________________________
Country ____________________________________________________________
Phone ___________________________ Fax ____________________________
Email address ____________________________________________________________

I would like to join the CIS-APS list service group and I agree to abide by the guidelines.

Signature: ___________________________ Date: ___________________________

CLINICAL IMMUNOLOGY SOCIETY
APS List Service
555 East Wells Street, Suite 1100
Milwaukee, WI 53202/USA
Email: info@clinimmsoc.org
Telephone: 414.224.8095 - Fax: 414.272.6070
CIS-AUTOIMMUNE POLYENDOCRINE SYNDROMES (APS) LISTSERV GUIDELINES

INTRODUCTION:
This E-mail Listserv has been set up to provide an easy way for professionals with an interest in APS to discuss issues of common interest. You can send an email to the server group. Your email will appear in the email file of everyone on the server list. If someone offers advice, that advice also appears in everyone’s email. A third person may disagree and join the conversation. We hope to generate many lively discussions. The server group may also be used to look for collaborators or new faculty members. This Listserv is set up as a communication tool to help you interact with your colleagues. It is closed to the general public.

GUIDELINES FOR POSTING MESSAGES:
Different people have different access privileges to the Internet. Your messages affect a large number of people. Please keep this in mind when sending a message to the group. Here are some specific guidelines to help keep things simple.

1. Do not use this list for commercial purposes or allow anyone else to use this list for commercial purposes.
2. Part of the purpose of the server group is to help us to build a community. To do this, we must be able to identify each other. At the end of your message, sign your email with your name, institution, address, phone number, fax number and email address. This will also allow people to contact you directly if they have a message that is not of general interest.
3. Do not send attachments in your message (attachments are files from another software program on your hard drive). Because people use a variety of different software programs, attachments cannot generally be opened by the entire group.
4. Your writing is a reflection of professionalism. Please spell check your messages and use the same rules for grammar and politeness that you would use in a paper letter. CAPITAL LETTERS ARE SEEN AS SHOUTING WORDS. Please use respect for your colleagues.
5. Keep ‘Subject’ lines relevant. If the topic changes, change the ‘Subject.’

We ask that all participants adhere to these guidelines in order to facilitate reasonable discussion, enhance the quality of the service and to make life easier for everyone who reads the list.

DISCLAIMER:
The communication provided by this Listserv is for educational or informational purposes only and is not intended to replace or constitute medical advice or treatments.

CIS intends that the information discussed on this Listserv is accurate. However, these discussions are between individual CIS members. Therefore, CIS disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this service, including without limitation merchantability or fitness for any particular purpose. In no event shall CIS be liable for any indirect, special, incidental or consequential damages arising out of any use of or reliance on any content or materials contained herein.

The Listserv is provided “AS IS” without any warranty, of any kind, express or implied. CIS is not responsible for any content posted by any user of this service. Any opinion expressed by a user does not necessarily represent the opinion of CIS and the user is solely responsible for same.

CIS does not assume and hereby disclaims any and all liability to any person or entity for any claims, damages, liability or other loss including, without limitation, any liability for injury or other damage resulting from any use of or reliance on this service or from the posting of any content or material by any third party.

No use of, or reliance on, information included on this Listserv shall be deemed to give rise to a physician-patient relationship. No information presented shall be deemed to present the only or necessarily the best method or procedure with respect to a matter discussed on this service; rather, any such material shall be acknowledged as only the approach or opinion of the discussant. The user assumes all risks of using the information discussed on this Listserv.
GENERAL MEETING INFORMATION

MEETING LOCATION
All educational sessions, posters, exhibits, and registration held as part of the CIS Annual Meeting will take place at the JW Marriott Marquis.

JW MARRIOTT MARQUIS
255 Biscayne Boulevard Way
Miami, FL 33131
P: (305) 421-8600

REGISTRATION DESK
JW Marriott Marquis ~ 3rd Floor, Met Ballroom Pre-function

REGISTRATION DESK HOURS
Wednesday, April 24
4:00pm – 7:00pm
Thursday, April 25
7:30am – 7:00pm

EXHIBIT HALL
JW Marriott Marquis ~ 3rd Floor, Met Ballroom 1 - 4

Exhibitors provide the latest information on products and services available to physicians, researchers and allied health professionals in the field of immunology. Take this valuable opportunity to meet with companies and organizations specializing in all areas of the immunology field.

EXHIBITOR MOVE-IN HOURS
Wednesday, April 24
2:00pm – 7:00pm
Thursday, April 25
6:00am – 11:30am

EXHIBIT & POSTER SESSION HOURS
Thursday, April 25
11:30am – 1:30pm
5:30pm – 7:30pm

POSTER SESSIONS
Poster sessions are held in the exhibit hall and authors will be present with their posters during exhibit hall hours. Lunch will be available during the afternoon poster session hours.

PUBLISHING OF ABSTRACTS
The abstracts submitted to the 2013 Update in PID are published in the April issue of Journal of Clinical Immunology, the official journal of the Clinical Immunology Society. Copies are available at the CIS registration desk.

ACCESSIBILITY
If you require special arrangements in order to fully participate in the CIS Update in PID, please speak with a CIS staff member at the registration desk.

NAME BADGES
All registered attendees at the CIS Update in PID will receive a name badge as part of their registration packet. These badges should be worn at all times as they will be used to control access to sessions and activities.

SMOKING
Smoking is prohibited at all CIS sessions and events.

EVALUATIONS
Delegates will have the opportunity to provide feedback on their experience at the 2013 Update in PID. After the meeting all registered delegates will receive an online evaluation to complete. Evaluations are an important part in helping us to improve our educational sessions so please take a moment to complete it!

CIS / BAXTER SCHOLARSHIP PROGRAM
Thanks to a generous grant from Baxter, we were able to offer one (1) $30,000 Fellowship Award and one (1) $30,000 Junior Faculty Award to two promising immunologists who have demonstrated a commitment to the study of primary immunodeficiency as a career path. Funding is to support the education and research endeavors of these individuals.

Congratulations to the Fellowship Award Winner:
Paul J. Maglione, MD PhD, Mt. Sinai Medical Center

Congratulations to the Junior Faculty Award Winner:
Sarah K. Nicholas, MD, Texas Children’s Hospital

NIT/FIT MEET & GREET RECEPTION
The members of the CIS New-Immuneologists-in-Training / Fellows-in-Training (NIT / FIT) Committee invite you to attend the NIT / FIT Reception on Thursday, April 25th from 5:30 – 7:30pm. This is an opportunity for Fellows and Trainees to network with their colleagues and senior faculty. Come and mingle with the future leaders in the field of immunology as you meet the committee members and discuss their professional and committee-related goals.
CONTINUING MEDICAL EDUCATION INFORMATION

PURPOSE
To understand how to treat primary immune deficiency diseases in the context of other diseases.

TARGET AUDIENCE
This program is designed for allergist-immunologists, primary care physicians, nursing professionals specializing in immunology and other medical professionals who treat primary immunodeficiency diseases.

LEARNING OBJECTIVES
• Provide advanced training for physicians and researchers working in the field of primary immune deficiency that covers diagnosis, therapy and future trends related to the care of patients with primary immune deficiencies.
• Facilitate interactions among clinicians of diverse training to promote multicenter clinical trials and to coordinate participation in existing clinical trials.
• Improve recognition of primary immune deficiencies.
• Improve understanding of the diagnostic issues and the pathophysiology of primary immune deficiencies.
• Improve understanding of the appropriate interventions for these diseases.

ACCME ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Clinical Immunology Society (CIS). The CIS is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT
The Clinical Immunology Society designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME
To claim CME credit and print out your CME certificate and/or certificate of attendance, please visit http://www.clinimmsoc.org/cme/pid2013.
2013 UPDATE IN PID PROGRAM COMMITTEE AND SPEAKER DISCLOSURES

James B. Bussel, MD
WEILL CORNELL MEDICAL CENTER
Amgen – Membership on advisory committee or review committee receiving Honoraria; Grant Recipient receiving Research Grant
GlaxoSmithKline – Membership on advisory committee or review committee receiving Honoraria; Grant Recipient receiving Research Grant
Cangene – Grant Recipient receiving Research Grant
Genzyme – Grant Recipient receiving Research Grant
IgG of America – Grant Recipient receiving Research Grant
Immunomedics – Grant Recipient receiving Research Grant;
Eisai – Membership on advisory committee or review committee receiving Honoraria; Grant Recipient receiving Research Grant
Shionogi – Membership on advisory committee or review committee receiving Honoraria; Grant Recipient receiving Research Grant
Sysmex – Grant Recipient receiving Research Grant

Manish J. Butte, MD, PhD
STANFORD UNIVERSITY
There are no relationships to disclose.

Charlotte Cunningham-Rundles, MD, PhD
MT. SINAI MEDICAL CENTER
Baxter – Membership on advisory committee or review committee receiving Consulting fee
Grifols – Membership on advisory committee or review committee receiving Consulting fee
Biotest – Membership on advisory committee or review committee receiving Consulting fee
CSL Behring – Membership on advisory committee or review committee receiving Consulting fee

Elie Haddad, MD, PhD
CHU STE-JUSTINE, UNIVERSITY OF MONTREAL
CSL Behring – Consulting and adboard committee receiving Honoraria

Steven M. Holland, MD
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH
There are no relationships to disclose.

Michael B. Jordan, MD
CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER
There are no relationships to disclose.

M. Louise Markert, MD, PhD
DUKE UNIVERSITY MEDICAL CENTER
There are no relationships to disclose.

Rebecca Marsh, MD
CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER
There are no relationships to disclose.

Eric Meffre, PhD
YALE UNIVERSITY SCHOOL OF MEDICINE
Nimbus Discovery Inc. – Consulting receiving Consulting fee

Joshua Milner, MD
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH
There are no relationships to disclose.

Jan A. Nolta, PhD
UC DAVIS INSTITUTE FOR REGENERATIVE CURES AND STEM CELL PROGRAM
There are no relationships to disclose.

Amy E. O’Connell, MD, PhD
BOSTON CHILDREN’S HOSPITAL
There are no relationships to disclose.

Jordan Orange, MD, PhD
BAYLOR COLLEGE OF MEDICINE
CSL behring – Consulting receiving Consulting fee
BPL laboratories – Consulting receiving Consulting fee
Baxter Healthcare – Consulting receiving Consulting fee; Speaking and Teaching receiving Consulting fee and Honoraria
Grifols USA – Consulting receiving Consulting fee
IIBT reference laboratories – Consulting receiving Consulting fee

John M. Routes, MD
MEDICAL COLLEGE OF WISCONSIN
Baxter Pharmaceuticals – Grant Recipient receiving Research Grant

PV Soeiro-Pereira, PhD
UNIVERSITY OF SÃO PAULO
There are no relationships to disclose.

Carsten Speckmann, MD
UNIVERSITY FREIBURG MEDICAL CENTER
There are no relationships to disclose.

Michael A. Spinner
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH
There are no relationships to disclose.

Kathleen E. Sullivan, MD, PhD
CHILDREN’S HOSPITAL OF PHILADELPHIA
There are no relationships to disclose.

David Teachey, MD
CHILDREN’S HOSPITAL OF PHILADELPHIA
There are no relationships to disclose.

Troy R. Torgerson, MD, PhD
UNIVERSITY OF WASHINGTON
Baxter Biosciences- Membership on advisory board receiving consulting fees; Grant Recipient receiving Research Grant
CSL Behring- Grant Recipient receiving Research Grant
MIAMI VISITOR INFORMATION

NEIGHBORHOODS
Miami’s cultural diversity is apparent from the moment you set foot on its soil and hear the rise and fall of a dozen different languages being spoken. It is an easygoing beach town, a refugee camp, and a 24-hour party all at once.

MIAMI BEACH
When talking about Miami, the beach is the best place to start. In the 1940s, when vacationers began to arrive, Miami Beach was the center of the action. Although years have passed and times have changed, the beach remains a perennial hot spot. Enormous luxury resorts such as Fontainebleau and Eden Roc rise majestically against the skyline. Shops and restaurants line the streets, and who could forget the miles of white sand beach?

SOUTH BEACH
Once home to a number of retired citizens and starving artists, South Beach has now risen to international fame as a popular vacation destination. Every block is packed with restaurants, bars, shops, and - of course - dance clubs, each trendier, more glamorous and cutting-edge than the last. One could spend days soaking in the sights and sounds of South Beach. Take a walking tour along Ocean Drive or down Lincoln Road, where the beautiful people come out to play. Whether it’s three in the morning or three in the afternoon, there is bound to be plenty to do.

BAL HARBOUR
Located on the northern end of Miami Beach, Bal Harbour is the most exclusive neighborhood in Greater Miami. Luxury resorts sit serenely amid the lush foliage and palatial homes. No visit to this district is complete — or even begun — without a visit to the Bal Harbour Shops. Versace, Louis Vuitton, Fendi and Prada are just a few of the fashion houses that have retail outlets in this shopping center. Plenty of fine dining can be found in Bal Harbour. (If you’re on a budget, this isn’t the place to dine or shop!)

DOWNTOWN MIAMI
Although primarily a business district, there’s a lot to see and do downtown. Tour the design district between Northeast 36th and 41st Streets, or check out the museums in the Metro-Dade Cultural Center. Shoppers will delight in the Bayside Marketplace with its retail shops, open-air crafts market, half-dozen restaurants and pier. The Port of Miami is next to Bayside, where you can easily find a boat to take you on a tour around the bay.

CORAL GABLES
Coral Gables is a gated enclave crisscrossed by canals, just a few minutes’ drive from Downtown Miami. This small, tree-lined village is home to many of Miami’s most famous attractions, including the Biltmore Hotel, Venetian Pool and Miracle Mile. Excellent shopping and dining can be found on the Miracle Mile as well as on the side streets surrounding it.

COCONUT GROVE
Although this bustling district is one of the oldest in Miami, it seems to just be hitting its prime. Full of energy and creativity, the Grove is as busy as South Beach, but in a different way. Instead of attracting models and body builders, it draws in artists, writers and patrons of the arts. There are hundreds of fabulous shops and restaurants crammed within this small area, most of them located on the CocoWalk or on the Streets of Mayfair. The Coconut Grove Playhouse is one of the best live theater venues in the southeastern United States.

LITTLE HAVANA
This area is located west of Brickell Avenue and runs along the thoroughfare known as Calle Ocho (Southwest 8th Street). Many immigrants and refugees from Cuba have settled here, along with natives of Colombia, Guatemala, Puerto Rico and other Latin American countries. It is in this district that you can enjoy authentic salsa music, indulge in a complete Cuban meal that’s light on your wallet, or try a steaming cup of shockingly strong café cubano in an outdoor cafe.

NORTH MIAMI/AVENTURA
While it may be slightly out of the way, Aventura is easy to reach even without a car, thanks to the shuttle buses that run regularly from the major downtown hotels to the Aventura Mall. The mall is well worth a day trip, as it boasts over 250 shops, restaurants and attractions. This district is also home to dozens of excellent restaurants, many of them specializing in “Floribbean” cuisine.

GOLF COURSES
CRANDON GOLF KEY BISCAYNE (7 miles)
Phone: 1-305-361-9129
18 holes – Par for course: 72
Designed by Robert Von Hagge and Bruce Devlin

MIAMI BEACH GOLF CLUB (6.5 miles)
Phone: 1-305-532-3350
18 holes – Par for course: 72
Designed by Arthur Hills

BILTMORE GOLF CLUB (6 miles)
Phone: 1-305-460-5364
18 holes – Par for course: 71
Designed by Donald Ross

FAMILY & CHILDREN’S ACTIVITIES
JUNGLE ISLAND (3 miles)
Phone: 1-305-400-7000
Tropical paradise featuring exotic animals, vibrant botanical bird sanctuary & wildlife habitat.
Fee: 32.95 USD

MIAMI CHILDREN’S MUSEUM (2 miles)
Phone: 1-305-373-5437
Dedicated to enriching children’s lives, with interactive exhibits & more.
Fee: 15.00 USD

MIAMI SEAQUARIUM (5 miles)
Phone: 1-305-361-5705
38-acre aquatic park featuring fantastic themed animal shows
Fee: 37.95 USD

METROZOO (20.5 miles)
Phone: 1-305-251-0400
Spend a day exploring this fascinating zoo with the family
Fee: 15.95 USD

For more information about Miami and the surrounding areas, visit the Miami Visitor Information Center.
MIAMI VISITOR INFORMATION

SHOPPING
AVENTURA MALL
19501 Biscayne Boulevard
Aventura, FL 33180
P: (305) 935-1110

Aventura Mall was voted Best Local Shopping Destination by the Miami Herald’s “Hot List” and ranks as one of the top five highest grossing malls in the country in sales per square foot. The 2.8 million square-foot multi-level mall recently completed a $22 million renovation featuring dramatic new architecture and distinctive design. Aventura Mall is also South Florida’s #1 shopping destination among international visitors. Aventura Mall is home to Nordstrom, Bloomingdale’s, Macy’s, Macy’s Men’s Home Furniture, JCPenney and Sears, more than 280 stores and restaurants, a 24-screen movie theater, and an artist-designed interactive playground, Rainbow Valley.

BAL HARBOUR SHOPS
9700 Collins Avenue
Miami Beach, FL 33154
P: (305) 866-0311

The Bal Harbour Shops are known throughout Miami as the one-stop-shop for all things designer. At this shopping center shoppers will find everything from luxury department stores like Saks Fifth Avenue to individual designer boutiques like Chanel, Gucci, Hermes, Prada, Jimmy Choo and many more. The Bal Harbour Shops also have quite a few delicious restaurants scattered throughout so you can keep your strength up so you shop but don’t drop.

BAYSIDE MARKETPLACE
401 Biscayne Boulevard, Suite R106
Miami, FL 33132
P: (305) 577-3344

To get the quintessential Miami experience, visit this lovely open-air market, where you can browse the artist’s carts, sip an iced drink and stroll along the pier. More than 100 shops and 30 restaurants make this a wonderful place to shop. This is more than just a mall—it is a sweet slice of south Florida life. Located next to the American Airlines Arena and the Port of Miami, this is a great place to spend a few hours.

LINCOLN ROAD
Between 16th & 17th Street
Miami, FL 33139
P: (305) 531-3442

A stroll down the Lincoln Road is a must for all those visiting the South Beach area. Traffic is not allowed on this Road that features some fabulous cinemas, bars, cafes, restaurants—you name it, it has it. It also houses the famous New World Symphony concert hall. Galleries that encourage budding artists also adorn the Lincoln Road; just the perfect place for those looking for some retail therapy at a leisurely pace minus the traffic.

LOCAL TOUR SERVICES

Everglades Adventure
P: 1-800-303-1503

Grand Miami Air Tour
Miami’s beautiful beaches and shoreline
P: 1-800-303-1503

Miami City Tour and Biscayne Cruise
Miami city tour and cruise along Biscayne Bay
P: 1-800-303-1503

Millionaires Row
Tour of Biscayne Bay’s Millionaires Row
Island Queen Cruises
P: (305) 379-5119

Vizcaya Museum & Gardens Tour
P: 1-800-303-1503

DINING

THE CAPITAL GRILLE (0.4 miles)
P: (305) 374-4500
Steakhouse
Open for lunch and dinner
Luscious dry-aged steaks, hand-carved chops and fresh seafood grace the menu of this outstanding, upscale restaurant.

CHOP HOUSE MIAMI (0.1 miles)
P: (305) 938-9000
Steakhouse
Open for lunch and dinner
“A Destination for those who still share the secret pleasures of red meat, well-cut and seriously served.” - New York Times

GRIMPA STEAKHOUSE (0.9 miles)
P: (305) 445-4757
Brazilian Steakhouse
Open for lunch and dinner

THE OCEANAIRE SEAFOOD ROOM (0.6 miles)
P: (305) 372-8862
Seafood
Open for lunch and dinner

GORDON BIERSCHE BREWERY RESTAURANT (0.7 miles)
P: (786) 425-1130
American
Open for lunch and dinner
Casual restaurant, sports entertainment
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30am – 8:00am</td>
<td><strong>Breakfast</strong> Met Ballroom Pre-function</td>
</tr>
<tr>
<td>8:00am – 8:15am</td>
<td><strong>GATA2 Deficiency: Extended Clinical Phenotype in 57 Patients</strong> Michael A. Spinner, NIAID, NIH</td>
</tr>
<tr>
<td>8:15am – 9:00am</td>
<td><strong>GATA2</strong> Steven M. Holland, MD, NIAID, NIH</td>
</tr>
<tr>
<td>9:00am – 9:45am</td>
<td><strong>HLH &amp; Killing</strong> Jordan S. Orange, MD, PhD, Baylor College of Medicine</td>
</tr>
<tr>
<td>9:45am – 10:00am</td>
<td><strong>A Novel 14 day Reduced Intensity Conditioning Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Allogeneic Hematopoietic Cell Transplantation of Patients with Hemophagocytic Lymphohistiocytosis Disorders</strong> Rebecca A. Marsh, MD, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>10:00am – 10:15am</td>
<td><strong>Morning Break</strong></td>
</tr>
<tr>
<td>10:15am – 11:45am</td>
<td><strong>PI3 Kinase Inhibitor &amp; BTK Inhibitor</strong> CD19/P13K/BTK mediates TLR function in human B-cells Eric Meffre, PhD, Yale University</td>
</tr>
<tr>
<td>10:45am – 11:15am</td>
<td><strong>IL-21R and PLCG2 mutations: Complex diseases illuminate basic pathways - B-cells and beyond</strong> Joshua D. Milner, MD, NIAID, NIH</td>
</tr>
<tr>
<td>11:15am – 11:45am</td>
<td><strong>Identification of a PI-3K PIK3CD Deficient Individual</strong> Michael B. Jordan, MD, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>11:30am – 11:45am</td>
<td><strong>Innate and Adaptive Defects of Uncharacterized Primary Immunodeficiencies Identified by Phospho-Mass Cytometry (CYTOF)</strong> Manish J. Butte, MD, PhD, Stanford University</td>
</tr>
<tr>
<td>11:45am – 12:30pm</td>
<td><strong>Guided Poster Session</strong> Met Ballroom 1 - 4</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Kathleen E. Sullivan, MD, PhD</td>
</tr>
<tr>
<td></td>
<td><strong>Poster #: 15</strong> Frequency of Lymphomas in a Cohort of Patients with Common Variable Immunodeficiency Cristina M. Kokron, MD, PhD, University of São Paulo School of Medicine</td>
</tr>
<tr>
<td></td>
<td><strong>Poster #: 33</strong> Lupus Patient with Impaired Receptor Editing has Heterozygous RAG2 Mutation Johan Walter, MD, PhD, Massachusetts General Hospital for Children</td>
</tr>
<tr>
<td></td>
<td><strong>Poster #: 45</strong> DOCK8 is Required for Actin Accumulation at the NK Cell Lytic Synapse and NK Cell Cytotoxic Function Melissa Mizesko, MD, Baylor College of Medicine</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td><strong>Lunch/Poster Viewing/Exhibit Hall Open</strong> Met Ballroom 1 - 4</td>
</tr>
<tr>
<td>1:30pm – 2:30pm</td>
<td><strong>Short Stories on How I Treat…</strong> ALPS</td>
</tr>
<tr>
<td>1:30pm – 1:50pm</td>
<td><strong>Rituximab in CViD in Lung Disease</strong> John M. Routes, MD, Medical College of Wisconsin</td>
</tr>
<tr>
<td>1:50pm – 2:10pm</td>
<td><strong>Cytopenias</strong> James B. Bussel, MD, Weill Cornell Medical Center</td>
</tr>
<tr>
<td>2:10pm – 2:30pm</td>
<td><strong>Cytopenias</strong> James B. Bussel, MD, Weill Cornell Medical Center</td>
</tr>
<tr>
<td>2:30pm – 2:45pm</td>
<td><strong>Afternoon Break</strong></td>
</tr>
<tr>
<td>2:45pm – 5:15pm</td>
<td><strong>Immune Reconstitution &amp; Immunomodulation in PID &amp; Autoimmunity</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Luigi Notarangelo, MD, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>2:45pm – 3:15pm</strong> Inflammatory Complications Charlotte Cunningham-Rundles, MD, PhD, Mt. Sinai Medical Center</td>
</tr>
<tr>
<td></td>
<td><strong>3:15pm – 3:30pm</strong> New Perspectives in Phagocytes Immunodeficiency: Impairment in the Generation of Neutrophil Extracellular Traps Paulo V. Soeiro-Pereira, MSc, University of São Paulo</td>
</tr>
<tr>
<td></td>
<td><strong>3:30pm – 3:45pm</strong> Colitis-Predominant XIAP Deficiency with Clinical response to TNF Alpha Inhibition Amy E. O’Connell, Boston Children’s Hospital</td>
</tr>
<tr>
<td>3:45pm – 4:15pm</td>
<td><strong>Reconstitution of Humoral Immunity after Hematopoietic Cell Transplantation for SCID</strong> Elie Haddad, MD, PhD, CHU Ste-Justine, University of Montreal</td>
</tr>
<tr>
<td>4:15pm – 4:30pm</td>
<td>**KRECs but not TRECs identify Patients with Delayed-Onset Adenosine Deaminase Deficiency in Neonatal Screening Carsten Speckmann, University Freiburg Medical Center</td>
</tr>
<tr>
<td>4:30pm – 4:45pm</td>
<td>**Response to Bacteriophage Φχ174 in Children with Partial DiGeorge Anomaly and in Children with Complete DiGeorge Anomaly after Cultured Postnatal Allogeneic Thymus Transplantation M. Louise Markert, MD, PhD, Duke University Medical Center</td>
</tr>
<tr>
<td>4:45pm – 5:15pm</td>
<td><strong>Immunomodulatory Properties of Mesenchymal Stem Cells Jan Nolta, PhD, University of California, Davis</strong></td>
</tr>
<tr>
<td>5:15pm – 5:30pm</td>
<td><strong>Open Discussion</strong></td>
</tr>
<tr>
<td>5:30pm – 7:30pm</td>
<td><strong>NIT/FIT Meet &amp; Greet Reception</strong> Met Ballroom 5 - 7</td>
</tr>
</tbody>
</table>
Walgreens Infusion Services is the nation's largest provider of home and alternate treatment site infusion services. With a staff of more than 1,400 clinicians and over 70 infusion pharmacies nationally, Walgreens Infusion Services IG Program treats patients with a wide range of conditions requiring IG therapy. IG trained clinicians and insurance experts are available to support you and your patients 24 hours a day every day. Last year Crescent Healthcare joined the Walgreens team, bringing together two clinical leaders in home and alternate site IG services.

Booth #: 111
CLINICAL IMMUNOLOGY SOCIETY
(414) 224-8095
www.clinimmsoc.org

The Clinical Immunology Society (CIS), established in 1986, is the key interdisciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. CIS is an international professional organization which includes more than 600 clinicians, investigators, and trainees. The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

Booth #: 113
ACCREDO HEALTH GROUP, INC.
Accredo Health Group, Inc., is a recognized leader in the specialty pharmacy industry, providing targeted therapy support to patients with rare and complex conditions for over 25 years. Accredo is one of the largest specialty pharmacy providers in the United States.

Booth #: 201
BAXTER BIOSCIENCE
Baxter provides purified plasma treatments containing antibodies called immunoglobulins that help Primary Immune Deficiency patients fight off infection. Immunoglobulins are also indicated to treat a number of conditions including Kawasaki Syndrome, Chronic Lymphocytic Leukemia (CLL) and Idiopathic Thrombocytopenic Purpura (ITP).

Booth #: 207
GRIFOLS
Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions — Bioscience, Diagnostic and Hospital — that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.
EXHIBITORS

Booth #: 208  
GENEDX  
GeneDx was founded in 2000 by two scientists from the National Institutes of Health (NIH) to address the needs of patients and clinicians in diagnosing rare inherited disorders. Currently, GeneDx offers testing for more than 350 rare Mendelian disorders, whole exome sequencing, oligonucleotide microarray-based testing for detecting chromosomal abnormalities, and next-gen panels for inherited cardiac disorders, neurological disorders, metabolic disorders, eye disorders, immunological disorders and mitochondrial disorders. Our highly trained and experienced physicians, geneticists, and genetic counselors work as a team to bring gene discoveries to clinical medicine for use in direct patient care. For more information, visit www.GeneDx.com or contact GeneDx@GeneDx.com.

Booth #: 209  
VIDARA THERAPEUTICS, INC.  
ACTIMMUNE® (interferon gamma-1b), a biologic response modifier, is a sterile, clear, colorless solution filled in a single-use vial for subcutaneous injection. ACTIMMUNE® is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD). CGD is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE® is also indicated for delaying time to disease progression in patients with Severe, Malignant Osteopetrosis. Severe, Malignant Osteopetrosis is an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and deficient phagocyte oxidative metabolism.

Booth #: 210  
THE BINDING SITE  
Binding Site is committed to the improvement of patient care by developing special protein assays and automated systems of the highest quality. Freelite®, developed and provided exclusively by Binding Site, is part of the standard-of-care for Myeloma diagnosis. We are also the market leaders for the investigation of immunoglobulin subclasses; our extensive portfolio includes assays for complement activity, optimized for the SPAPLUS, our flexible, reliable analyzer to meet any laboratory's changing needs. With our extensive development expertise, patented antibody production and focus on education, we provide healthcare professionals with relevant tools to optimize workflow and improve patients' lives.

Booth #: 211  
BIOTEST  
Biotest Pharmaceuticals Corporation (BPC) researches and manufactures biotherapeutic products with a specialization in immunology and hematology. BPC is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products which are antibody specific to high titer for treatment of modality.

Booth #: 212  
BIO PRODUCTS LABORATORY  
Bio Products Laboratory services the U.S. market with Gammaplex Immune Globulin Intravenous (Human), 5% liquid. BPL’s Mission is to provide continuous and competitive supply of high quality plasma delivered products to a growing global market through investing in the latest research, technology and manufacturing methods and by ensuring ongoing and responsive support to health professionals throughout the world.

Booth #: 213  
WORLD ALLERGY ORGANIZATION  
The World Allergy Organization (WAO) is an international umbrella organization whose members consist of 89 regional and national allergology and clinical immunology societies from around the world. By collaborating with member societies, WAO is a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a worldwide alliance of allergy and clinical immunology societies in nearly 100 countries around the globe. Visit our booth to learn more about the WAO Symposium on Immunotherapy and Biologics to be held 13-14 December 2013 in Chicago, IL, USA. The Symposium is the first global meeting of its kind and will welcome basic and translational scientists, clinical immunologists, allergists and researchers interested in exploring the exciting field of Immunotherapy and Biologics.

Booth #: 307  
CSL BEHRING  
CSL Behring is a global leader in plasma protein therapeutics. The company manufactures safe and effective plasma-derived and recombinant therapies for treating coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and for use in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information: www.cslehring-us.com.

Booth #: 308  
MEDICAL COLLEGE OF WISCONSIN  
The Clinical Immunodiagnostic & Research Laboratory (CIRL) at MCW offers diagnostic flow cytometry for Primary Immunodeficiency (PID) diseases. CIRL and CHW’s PID Clinics function as Jeffrey Modell Diagnostic & Patient Referral Center in Wisconsin since 2007. IDC is first in USA to pioneer statewide newborn screening for Severe Combined Immunodeficiency.

Booth #: 310  
VIROPHARMA, INC.  
Our product CINRYZE® (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder.

Booth #: 311  
AXELACARE  
AxelaCare specializes in the administration of Immune Globulin IVIG and other infusible medications. We provide medications, treatment management, insurance support, home infusion nursing and advocacy services for patients with rare and chronic disease. Our proprietary clinical outcomes measurement system uses our infusion nurses and patients to enter physical assessments, quality of life, and disability/activities of daily living data into iPads. Validated data is collected and presented in simple graphical display via secure web access to clinicians to determine optimal care based on dose versus time and collected outcomes. Our mission is to empower people in the pursuit and delivery of exceptional patient care.
EXHIBITORS

Booth #: 312
BIORX
BioRx is a national provider and distributor of select specialty pharmaceuticals, related supplies, and clinical, reimbursement and in-home support services. BioRx specializes in the following disease/therapy areas: 1) hemophilia and related bleeding disorders, including the provision of anti-hemophilic clotting factors and highly customized support services, 2) immunology therapy (IVig and SCig), including related pumps, supplies and nursing services, 3) augmentation therapy for alpha-1 antitrypsin deficiency, 4) infusion and self-injection therapies for hereditary angioedema, and 5) enteral and parenteral infusion therapies for nutrition and digestive disorders.

Booth #: 314
GEORGETOWN UNIVERSITY IMMUNOLOGY CENTER
Bellanti's long-awaited *Immunology IV: Clinical Applications in Health and Disease* is a completely rewritten 2012 edition of his classic textbook. The book brings the science of immunology to clinical practice. Each chapter is written by a noted authority who contributes state-of-the-art knowledge on each particular topic in a 1000+ page volume containing 25 chapters, over 800 vivid colored figures accompanied by an online multilevel teaching format with animations/hyperlinks, clinical case studies with interactive Q & A and continual clinically relevant updates. Come visit us in the Exhibit hall, Booth 314, for a book signing.
<table>
<thead>
<tr>
<th>Poster #</th>
<th>ID</th>
<th>Title</th>
<th>Keywords</th>
<th>Presenting Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2421</td>
<td>EFFECT OF LYSOFYLLINE ON THE IMMUNE RESPONSE IN ISLET TRANSPLANT PATIENTS</td>
<td>Autoimmunity; Transplant Immunology</td>
<td>Ana Hernandez, University of Miami Miller School of Medicine</td>
</tr>
<tr>
<td>2</td>
<td>2367</td>
<td>PRIMARY IMMUNODEFICIENCIES WITH DYSREGULATION</td>
<td>PID</td>
<td>Analía Gisela Seminario, Ricardo Gutiérrez Children's Hospital</td>
</tr>
<tr>
<td>3</td>
<td>2368</td>
<td>FOLLICULAR BRONCHIOLITIS AND PHENOTYPE ASSOCIATED WITH CD 25 DEFICIENCY</td>
<td>PID</td>
<td>Analía Gisela Seminario, Ricardo Gutiérrez Children's Hospital</td>
</tr>
<tr>
<td>4</td>
<td>2363</td>
<td>DEFECTS IN IL-12 / IFN-Y AXIS: A NEW PERSPECTIVE ON DEVELOPMENT AND ESTABLISHMENT OF WHEEZING</td>
<td>Immediate Hypersensitivity</td>
<td>Angela Falci, University of São Paulo</td>
</tr>
<tr>
<td>5</td>
<td>2315</td>
<td>THE SPECTRUM OF GUILLAIN-BARRE SYNDROME (GBS) IN PEDIATRICS – OVERLAP OF MILLER-FISHER (MFS), MOTOR-SENSORY (MS), AND AUTONOMIC (A) VARIANTS</td>
<td>Host Microbial Interactions/Pathogen Discovery; Autoimmunity</td>
<td>Annick Gaye, Catholic University of Louvain, Belgium</td>
</tr>
<tr>
<td>6</td>
<td>2362</td>
<td>KINETICS OF IgM AND IgA ANTIBODY RESPONSE TO 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINATION IN HEALTHY SUBJECTS</td>
<td>PID</td>
<td>Antony Parker</td>
</tr>
<tr>
<td>7</td>
<td>2415</td>
<td>MOLECULAR AND STRUCTURAL CHARACTERIZATION OF A NOVEL MUTATION IN BRUTON TYROSINE KINASE</td>
<td>PID</td>
<td>Artemio M Jongco, Feinstein Institute of Medical Research</td>
</tr>
<tr>
<td>8</td>
<td>2433</td>
<td>NORMAL B-CELL FUNCTION WITHOUT B-CELLS: AN UNRESOLVED PUZZLE</td>
<td>PID</td>
<td>Blas Javier Larrauri, British Hospital of Buenos Aires</td>
</tr>
<tr>
<td>9</td>
<td>2310</td>
<td>STRONGYLOIDES INFECTION OF IGA DEFICIENT HOST IN NON-ENDEMIC REGION</td>
<td>Host Microbial Interactions/Pathogen Discovery; Mucosal Immunology</td>
<td>Bob Geng, UCLA Medical Center</td>
</tr>
<tr>
<td>10</td>
<td>2395</td>
<td>PRIMARY CILIARY DYSKINESIA (PCD) WITH NORMAL CILIARY STRUCTURE ON ELECTRON MICROSCOPY (EM) AND ASSOCIATED GENE MUTATIONS</td>
<td>Genetics</td>
<td>Bob Geng, UCLA Medical Center</td>
</tr>
<tr>
<td>11</td>
<td>2419</td>
<td>A SUCCESSFUL PREGNANCY AND DELIVERY IN A PATIENT WITH ATAXIA-TELANGECTASIA</td>
<td>PID</td>
<td>Burcin Uygungil, Johns Hopkins Hospital</td>
</tr>
<tr>
<td>12</td>
<td>2432</td>
<td>UNMASKING IMMUNE DEFICIENCY IN AUTOIMMUNITY</td>
<td>Autoimmunity; PID</td>
<td>Christina C Price, Yale University School of Medicine</td>
</tr>
<tr>
<td>13</td>
<td>2349</td>
<td>AN UNUSUAL PRESENTATION OF MONOMAC</td>
<td>PID; Genetics</td>
<td>Christina Gagliardo, New York Presbyterian Hospital - Columbia University Medical Center</td>
</tr>
<tr>
<td>14</td>
<td>2231</td>
<td>SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) FROM A BROWN RECLUSE SPIDER BITE</td>
<td>PID</td>
<td>Christopher Dandoy, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>15</td>
<td>2446</td>
<td>FREQUENCY OF LYMPHOMAS IN A COHORT OF PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY</td>
<td>PID</td>
<td>CM Kokron, University of São Paulo School of Medicine</td>
</tr>
<tr>
<td>16</td>
<td>2455</td>
<td>CASE REPORT: LEPROSY ASSOCIATED TO COMMON VARIABLE IMMUNODEFICIENCY</td>
<td>PID</td>
<td>CM Kokron, University of São Paulo School of Medicine</td>
</tr>
<tr>
<td>17</td>
<td>2437</td>
<td>ATYPICAL SCID WITH CD4 LYMPHOPENIA, HYPERGAMMAGLOBULINEMIA, AND NEUTROPENIA PRESENTING WITH DISSEMINATED VACCINE-STRAIN VARICELLA AND RUBELLA INFECTIONS</td>
<td>Host Microbial Interactions/Pathogen Discovery; PID</td>
<td>Diana K. Bayer, Baylor College of Medicine and Texas Children's Hospital</td>
</tr>
<tr>
<td>18</td>
<td>2325</td>
<td>MULTIPLE GENE EXPRESSION ANALYSIS IN CD4, CD8 AND CD19 SUBSETS FOR PATIENTS AT-RISK AND WITH TYPE 1 DIABETES</td>
<td>Autoimmunity</td>
<td>Dongmei Han, University of Miami Miller School of Medicine</td>
</tr>
<tr>
<td>19</td>
<td>2392</td>
<td>TIMELY FOLLOW-UP OF A GATA2 DEFICIENCY PATIENT AS PREDICTOR OF SUCCESSFUL TREATMENT</td>
<td>Transplant Immunology</td>
<td>Eleonora Gambineri, Anna Meyer Children's Hospital, Department of Sciences for Woman and Child's Health, University of Florence</td>
</tr>
<tr>
<td>20</td>
<td>2330</td>
<td>THYMUS TRANSPLANTATION IN A THREE YEAR OLD CHILD WHO DID NOT DEVELOP SUFFICIENT NAIVE CD4 T CELLS AFTER PARENTAL BONE MARROW STEM CELL TRANSPLANTATION</td>
<td>Transplant Immunology; PID</td>
<td>Elizabeth A. McCarthy, Duke University Medical Center</td>
</tr>
<tr>
<td>21</td>
<td>2255</td>
<td>IDENTIFICATION AND VALIDATION OF SHRIMP-TROPOMYSIN CD4 T CELL EPITOPES</td>
<td>Immediate Hypersensitivity</td>
<td>Eugene V. Raskov, ARUP Institute for Clinical and Experimental Pathology</td>
</tr>
<tr>
<td>22</td>
<td>2342</td>
<td>SEVERE COMBINED IMUNODEFICIENCY DUE TO ADENOSINE DEAMINASE DEFICIENCY: EVIDENCE FROM THREE CASE REPORTS</td>
<td>PID</td>
<td>Ferah Genel, Dr.Behçet Uz Children's Hospital</td>
</tr>
<tr>
<td>Poster #</td>
<td>ID</td>
<td>Title</td>
<td>Keywords</td>
<td>Presenting Author</td>
</tr>
<tr>
<td>----------</td>
<td>------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>23</td>
<td>2438</td>
<td>TACKLING THE HETEROGENEITY IN PATIENTS WITH CHRONIC MUCOCUTANEOUS CANDIDIASIS CAUSED BY MUTATIONS IN THE STAT1 DNA-BINDING DOMAIN</td>
<td>PID; Genetics</td>
<td>Heidi Schaballie</td>
</tr>
<tr>
<td>24</td>
<td>2418</td>
<td>STRUCTURAL FEATURES OF THE PEYER'S PATCHES OF THE SMALL INTESTINE UNDER THE INFLUENCE OF CYCLOPHOSPHAMIDE</td>
<td>Mucosal Immunology</td>
<td>Helen Morozova</td>
</tr>
<tr>
<td>25</td>
<td>2332</td>
<td>SERUM INTERLEUKIN-18 AS A POTENTIAL PREDICTOR OF RESPONSE TO INTERFERON/ribavirin THERAPY IN HCV-INFECTED EGYPTIAN PATIENTS</td>
<td>Host Microbial Interactions/Pathogen Discovery</td>
<td>Howayda M Hassoba, FOM/SCU</td>
</tr>
<tr>
<td>26</td>
<td>2357</td>
<td>DOUBLE NEGATIVE T CELLS IN PEDIATRIC AUTOIMMUNITY</td>
<td>Autoimmunity</td>
<td>James A. Tarbox, Washington University in St. Louis</td>
</tr>
<tr>
<td>27</td>
<td>2456</td>
<td>AUTOLOGOUS TGF-ß IS REQUIRED FOR FOXP3 INDUCTION, IL-10 EXPRESSION, AND SUPPRESSIVE FUNCTION OF HUMAN TR1 CELLS</td>
<td>Autoimmunity</td>
<td>James W. Verbsky, Medical College of Wisconsin</td>
</tr>
<tr>
<td>28</td>
<td>2389</td>
<td>SERUM IMMUNOGLOBULIN LEVELS ARE ASSOCIATED WITH HEALTH-RELATED QUALITY OF LIFE IN HUMORAL PRIMARY IMMUNODEFICIENCIES</td>
<td>PID</td>
<td>Jason Catanzaro, Case Western Reserve University</td>
</tr>
<tr>
<td>29</td>
<td>2269</td>
<td>ATOPIC DERMATITIS: MORE THAN ONE TREATMENT (A BRIEF CASE)</td>
<td>Genetics</td>
<td>Jennifer Harder, IMUNOPED</td>
</tr>
<tr>
<td>30</td>
<td>2442</td>
<td>SPOROTRHEX SCHENCKII LYMPHADENITIS IN A BOY WITH X-LINKED CHRONIC GRANULOMATOUS DISEASE</td>
<td>PID</td>
<td>Jennifer Leiding, University of South Florida</td>
</tr>
<tr>
<td>31</td>
<td>2246</td>
<td>AN UNCOMMON PRESENTATION OF COMMON VARIABLE IMMUNODEFICIENCY</td>
<td>PID</td>
<td>Jerome A Sigua, Medical College of Wisconsin</td>
</tr>
<tr>
<td>32</td>
<td>2366</td>
<td>TGFß REGULATES Pin1 STABILITY IN UBIQUITIN DEPENDENT MANNER</td>
<td>Mucosal Immunology</td>
<td>Jiyoung OH, University of Texas Southwestern Medical Center</td>
</tr>
<tr>
<td>33</td>
<td>2450</td>
<td>LUPUS PATIENT WITH IMPAIRED RECEPTOR EDITING HAS HETEROZYGOUS RAG2 MUTATION</td>
<td>Autoimmunity; PID</td>
<td>Jolan Walter, MassGeneral Hospital for Children</td>
</tr>
<tr>
<td>34</td>
<td>2275</td>
<td>AN ATYPICAL CASE OF MHCI EXPRESSION DEFICIENCY TREATED WITH BONE MARROW TRANSPLANT</td>
<td>Transplant Immunology</td>
<td>Joud Hajjar</td>
</tr>
<tr>
<td>35</td>
<td>2354</td>
<td>NEWLY DIAGNOSED CVID IN A PATIENT FOLLOWING TREATMENT FOR OSTEOSARCOMA</td>
<td>PID</td>
<td>Kara Crosby</td>
</tr>
<tr>
<td>36</td>
<td>2439</td>
<td>SCIG VS IVIG: LET'S GIVE PATIENTS THE CHOICE!</td>
<td>PID</td>
<td>Kathryn Samaan</td>
</tr>
<tr>
<td>37</td>
<td>2345</td>
<td>SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS (IGSC), 20%: INTERIM ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)</td>
<td>PID</td>
<td>Leman Yel</td>
</tr>
<tr>
<td>38</td>
<td>2348</td>
<td>THE ROLE OF PERFLUOROOCTANE SULFONATE (PFOS) AS A POTENTIAL ENVIRONMENTAL TRIGGER OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN AN IN UTERO MOUSE STUDY</td>
<td>Autoimmunity</td>
<td>Kristin Midgett, Medical University of South Carolina</td>
</tr>
<tr>
<td>39</td>
<td>2430</td>
<td>NOVEL GAiN OF FUNCTiON MUTATiON iN STAT1 ASSOCiATED WiTH DiSSEMiNATED ZYGOMYCOSiS</td>
<td>PID</td>
<td>Mary E Hanks</td>
</tr>
<tr>
<td>40</td>
<td>2272</td>
<td>EFfECT OF XIINKANG CAPSULE ON MCP-1, VCAM-1, TNF-aEXPRESSION, NF-KB ACTIVATION IN VASCULAR SMOOTH MUSCLE OF RABBITS INDUCED BY HOMOCYSTEINE</td>
<td>Host Microbial Interactions/Pathogen Discovery</td>
<td>Liang Xuguo</td>
</tr>
<tr>
<td>41</td>
<td>2253</td>
<td>DEVELOPMENT OF NOVEL MOUSE MODELS OF AUTOIMMUNE DISEASE AND FIBROSIS</td>
<td>Autoimmunity; Genetics</td>
<td>Madhumita Ray</td>
</tr>
<tr>
<td>42</td>
<td>2305</td>
<td>ESTABLISHMENT OF NEWBORN SCREENING FOR SCID / SEVERE T LYMPHOCYTOPENIA IN SÃO PAULO</td>
<td>PID</td>
<td>Marilia Kanegae, Institute of Biomedical Sciences</td>
</tr>
<tr>
<td>43</td>
<td>2430</td>
<td>NOVEL GAIN OF FUNCTION MUTATION IN STAT1 ASSOCIATED WITH DISSEMINATED ZYGOMYCOSIS</td>
<td>Genetics</td>
<td>Mary E Hanks</td>
</tr>
<tr>
<td>44</td>
<td>2429</td>
<td>DOCK8 IS REQUIRED FOR ACTIN ACCUMULATION AT THE NK CELL LYTIC SYNAPSE AND NK CELL CYTOTOXIC FUNCTION</td>
<td>PID</td>
<td>Melissa Mizesko, Baylor College of Medicine</td>
</tr>
<tr>
<td>Poster #</td>
<td>ID</td>
<td>Title</td>
<td>Keywords</td>
<td>Presenting Author</td>
</tr>
<tr>
<td>----------</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>46</td>
<td>2311</td>
<td>US IMMUNOLOGISTS PRESCRIBE THE SAME DOSES OF SCIG AND IVIG FOR TREATMENT OF PID</td>
<td>PID</td>
<td>Melvin Berger, CSL Behring LLC, King of Prussia, PA, USA</td>
</tr>
<tr>
<td>47</td>
<td>2270</td>
<td>PROINFLAMMATORY CYTOKINE GENE POLYMORPHISMS IN PATIENTS WITH ISCHEMIC HEART FAILURE</td>
<td>Genetics</td>
<td>Mona Hedayat, Boston Children's Hospital, Harvard Medical School</td>
</tr>
<tr>
<td>48</td>
<td>2377</td>
<td>A CASE OF RECURRENT MUCOCUTANEOUS CANDIDIASIS</td>
<td>PID</td>
<td>Nikita Raje, Children's Mercy Hospital &amp; Clinics</td>
</tr>
<tr>
<td>49</td>
<td>2426</td>
<td>DECREASED PROTEIN EXPRESSION OF NADPH OXIDASE RELATED TO MUTATION OF THE GENE ENCODING p47phox OF A GIRL WITH AUTOSOMAL CHRONIC GRANULOMATOUS DISEASE</td>
<td>PID</td>
<td>Nuria Bengala Zorro, Institute of biomedical Sciences</td>
</tr>
<tr>
<td>50</td>
<td>2383</td>
<td>CLINICAL CHARACTERISTICS OF INFANTS IDENTIFIED BY THE CONNECTICUT NEWBORN SCREEN FOR SEVERE COMBINED IMMUNE DEFICIENCY</td>
<td>PID</td>
<td>Odelya E Pagovich, Yale University School of Medicine</td>
</tr>
<tr>
<td>51</td>
<td>2280</td>
<td>COMMON VARIABLE IMMUNODEFIciENCY OR RITUXiMAB ADVERSE REACTION?</td>
<td>Autoimmunity; PID</td>
<td>Patricia Roessler</td>
</tr>
<tr>
<td>52</td>
<td>2409</td>
<td>IMPROVED IgG3 LEVELS DURING SUBCUTANEOUS IMMUNOGLOBULIN THERAPY CORRELATED WITH REDUCED INFECTION RATE IN A WOMAN WITH COMMON VARIABLE IMMUNE DEFICIENCY</td>
<td>Complement and C1inh</td>
<td>Ralph Scott Shapiro, Midwest Immunology Clinic</td>
</tr>
<tr>
<td>53</td>
<td>2447</td>
<td>USE OF A 20% SUBCUTANEOUS IMMUNOGLOBULIN SOLUTION (HIZENTRA, Y) ALLOWS FOR LOWER TOTAL DOSING VOLUMES AND FEWER TREATMENT DAYS PER WEEK COMPARED TO A 16% SUBCUTANEOUS SOLUTION</td>
<td>PID</td>
<td>Ralph Scott Shapiro, Midwest Immunology Clinic</td>
</tr>
<tr>
<td>54</td>
<td>2370</td>
<td>ASSESSING THE VIAL REDUCTION ASSOCIATED WITH 30 GRAM GAMGMAGARD LIQUID VIAL USE IN TREATING PRIMARY IMMUNODEFIciENCY (PI) PATIENTS IN REAL WORLD</td>
<td>PID</td>
<td>Ravi Iyer, Baxter Healthcare Corp</td>
</tr>
<tr>
<td>55</td>
<td>2291</td>
<td>MULTI-MODAL TREATMENT OF SEVERE TOXIC SHOCK LIKE SYNDROME (TSLS) WITH IV-IGG, INFLIXIMAB AND TOPICAL PIMECROLIMIS CREAM</td>
<td>Autoimmunity; Immediate Hypersensitivity</td>
<td>Robert A. Dracker</td>
</tr>
<tr>
<td>56</td>
<td>2431</td>
<td>THE EXPANDING CLINICAL SPECTRUM OF ADENOSINE DEAMINASE (ADA) DEFICIENCY INCLUDES FEATURES OF METABOLIC SYNDROME</td>
<td>PID</td>
<td>Robert Sokolic, National Human Genome Research Institute</td>
</tr>
<tr>
<td>57</td>
<td>2408</td>
<td>SPECIFIC ANTIBODY DEFICIENCY IN A GIRL WITH PENTASOMY X CHROMOSOME</td>
<td>PID; Genetics</td>
<td>Rongras Damrongwatanasuk, University of South Florida</td>
</tr>
<tr>
<td>58</td>
<td>2451</td>
<td>SECRETORY LEUKOCYTE PROTEASE INHIBITOR IN CONJUNCTIVAE AFFECTED BY OCULAR CIMCTRICAL PEMPHIGOID</td>
<td>Autoimmunity; Mucosal Immunology</td>
<td>Rony Greenberg, Massachusetts Eye Research and Surgery Institution</td>
</tr>
<tr>
<td>59</td>
<td>2435</td>
<td>HARMONIN AUTOANTIBODIES MEASURED BY LIPS AS SPECIFIC MARKERS FOR THE DIFFERENTIAL DIAGNOSIS OF IPLEX AND IPLEX-LIKE SYNDROMES</td>
<td>Autoimmunity</td>
<td>Rosa Bacchetta, San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy</td>
</tr>
<tr>
<td>60</td>
<td>2292</td>
<td>IMMUNE DYSFUNCTION WITH COENZYME Q10 DEFICIENCY IMPROVES AFTER COENZYME Q10 REPLACEMENT IN A FOUR YEAR-OLD CHILD WITH RECURRENT INFECTIONS</td>
<td>PID</td>
<td>Samira Farough, MassGeneral Hospital for Children</td>
</tr>
<tr>
<td>61</td>
<td>2420</td>
<td>INFECTION INCIDENCE AND ANTIBiotic USAGE IN PRIMARY IMMUNE DEFICIENCY PATIENTS ON IMMUNOGLOBULIN THERAPY: RESULTS FROM THE IMMUNOGLOBULIN DIAGNOSIS, EVALUATION, AND KEY LEARNINGS (IDEAL) PATIENT REGISTRY PROGRAM</td>
<td>PID</td>
<td>Sean Kearns, Coram Clinical Trials</td>
</tr>
<tr>
<td>62</td>
<td>2440</td>
<td>ANALYSIS OF PHYSICAL AND MENTAL QUALITY OF LIFE MARKERS IN PRIMARY IMMUNE DEFICIENCY PATIENTS ON IMMUNOGLOBULIN THERAPY: RESULTS FROM THE IMMUNOGLOBULIN DIAGNOSIS, EVALUATION, AND KEY LEARNINGS (IDEAL) PATIENT REGISTRY PROGRAM</td>
<td>PID</td>
<td>Sean Kearns, Coram Clinical Trials</td>
</tr>
<tr>
<td>63</td>
<td>2412</td>
<td>DOCK-8 DEFICIENCY- A CASE OF COMBINED IMMUNODEFIciENCY, EOSINOPHILIA AND ATOPY WITHOUT ELEVATED SERUM IgE</td>
<td>PID</td>
<td>Shanmuganathan Chandrakasan, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>64</td>
<td>2449</td>
<td>HEMOPHAGOCYTIC LYMPHOPROLIFERATIVE SYNDROME LIKE PRESENTATION OF AUTOMMUNE LYMPHOPROLIFERATIVE SYNDROME IN MONOZYGOTIC TWINS</td>
<td>PID</td>
<td>Shanmuganathan Chandrakasan, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>65</td>
<td>2458</td>
<td>CLINICAL SPECTRUM AND OUTCOMe OF HEMATOPOIETIC CELL TRANSPLANT FOR PATIENTS WITH NEMO DEFECT: A SINGLE CENTER EXPERIENCE</td>
<td>PID</td>
<td>Shanmuganathan Chandrakasan, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>Poster #</td>
<td>ID</td>
<td>Title</td>
<td>Keywords</td>
<td>Presenting Author</td>
</tr>
<tr>
<td>---------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>66</td>
<td>2396</td>
<td>ALLOGENIC TRANSPLANTATION FOR X-LINKED HYPER IgM SYNDROME - A SINGLE INSTITUTION EXPERIENCE</td>
<td>PID</td>
<td>Sharat Chandra, Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>67</td>
<td>2365</td>
<td>ABNORMAL NEUTROPHIL OXIDATIVE BURST (NOXB) IN A 72-YEAR OLD MALE WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)</td>
<td>PID</td>
<td>Shefali Anil Samant, Mayo Clinic</td>
</tr>
<tr>
<td>68</td>
<td>2376</td>
<td>CASE REPORT OF 2 PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY (CVID) AND DEBILITATING CHRONIC URTICARIA/ANGIOEDEMA (CUA)</td>
<td>Autoimmunity; PID</td>
<td>Solrun Melkorka Maggadottir, Children's Hospital of Philadelphia</td>
</tr>
<tr>
<td>69</td>
<td>2416</td>
<td>IMMUNE DYSREGULATION, TELOMERE SHORTENING, AND LIVER DISEASE IN A PEDIATRIC PATIENT: A THERAPEUTIC DILEMMA</td>
<td>PID</td>
<td>Timothy Lax, Massachusetts General Hospital</td>
</tr>
<tr>
<td>70</td>
<td>2369</td>
<td>DELAYED RECOGNITION AND TREATMENT OF HAE</td>
<td>Complement and C1inh</td>
<td>Vivian Cino, Joe Dimaggio Childrens Hospital</td>
</tr>
<tr>
<td>71</td>
<td>2338</td>
<td>GNATHOSTOMA SPINIGERUM: IMMUNODEPRESSION IN EXPERIMENTAL INFECTED MICE</td>
<td>Host Microbial Interactions/Pathogen Discovery</td>
<td>Wilai Saksirisampant</td>
</tr>
<tr>
<td>72</td>
<td>2380</td>
<td>PREDICTION OF EARLY/IMMEDIATE AND LONG-TERM OUTCOME FOLLOWING RENAL TRANSPLANTATION USING PERIOPERATIVE MEASUREMENTS OF SELECTED LEVELS OF COMPLEMENT-DERIVED ANAPHYLATOXINS AND MOLECULES</td>
<td>Complement and C1inh; Transplant Immunology</td>
<td>Wojciech Blogowski, Pomeranian Medical University in Szczecin</td>
</tr>
<tr>
<td>73</td>
<td>2381</td>
<td>CLINICAL ANALYSIS OF COMPLEMENT-DERIVED ANAPHYLATOXINS AND MOLECULES IN HUMAN ADIPOSE TISSUE</td>
<td>Complement and C1inh</td>
<td>Wojciech Blogowski, Pomeranian Medical University in Szczecin</td>
</tr>
</tbody>
</table>
Save the Date!

2014 CIS Annual Meeting: Primary Immune Deficiency Diseases North American Conference
APRIL 10 – 13, 2014 • BALTIMORE, MD